No idea, looks like we have gone for target market China and I believe Potnak pointed out early doors that Aus was a feeder market for them. Maybe our resident t.ats could provide some insight into it.
I'm super content with where we are now that the safety committee has given the green light for the next cohort and even exceeded my expectations by going dual by adding the multi-ascending after just 3 cohorts. The price is what it is and will catch up once ph1a results are in around end of this December.
Absolutely Basser, Dr Reader has in my opinion just done the masterstroke with the latest 2 patents this year. But 1802 has 2 existing patents with named indicators all you have to do is look at the market sizes for those indications to really understand why Tyk2 is hot hot hot.
Here are the patents in question, I have also listed the Tyk2 Japan one as well-
June 2023- 1801
The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders.
1802-
The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology.
Tyk2 Japan and China patent 2017-
This patent* describes compounds that inhibit JAK kinase enzyme function, in particular TYK2 kinase. It also describes the use of these compounds in the treatment of disease mediated by these kinase enzymes, including autoimmune diseases such as multiple sclerosis, psoriasis and inflammatory bowel disease.
The granting of the Japanese patent and the imminent granting of the Chinese patent mean that Sareum will have approved patent protection in Japan and China for its TYK2 inhibitor programme. Similar patent protection in Europe was announced on 10 November 2014 and the Company expects that similar patents will be granted in other major markets, including the USA, in due course.
* Japanese Patent no. 6239118, Chinese Patent Application no. 201380080517X
1802 (the biggy in most investors eyes) again a 100% owned Tyk2/Jak1 cancer compound likely also once daily capsule as per AGM using 1801 study as testing pad. Twice world-wide patent protected with the last 2 patents for the first time in our history naming target indications-
Euro patent grant-
The patent will come into effect on 4 May 2022.
The patent (EPO Patent no. EP3528806) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat T-cell acute lymphoblastic leukaemia (T-ALL - a cancer of a particular type of white blood cell called a T lymphocyte) and other cancers that are dependent on TYK2 kinase for survival. This programme is in preclinical development".
- And the US patent grant in 2021-
The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase.
Many happy returns chaps- you don't get patents granted if the science is dud.
As Sad posted the potential market size for what 1801 can potentially treat/cure is clear for everyone to see.
What is also prevelant in the pharma industry is companies licencing or buying out based on future projected sales as can be seen from these 2 articles-
https://www.toptal.com/finance/valuation/biotech-valuation
https://www.fiercebiotech.com/biotech/spying-devilish-deal-astrazeneca-pays-666-premium-buy-genomic-medicine-biotech
Every reason to be positive, however, lets finish ph1a and see how things stand.
I posted this earlier this year when we we're pre-clinical-
Yes we are pre-clinical, however, the pwc report says makes note of 'significant competition for differentiated assets and de-risked assets remains' which Sareum believe both our Tyk2's to be and with the FDA Sotyktu approval adds further validation to the Tyk2 class- but again we are Tyk2/Jak1 and superior.
Also note these are pre-clinical $billion deals from 2020-
https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020#58f9e8e8-c33b-42f5-a757-9a9d48d9e55c
Notable pre-clinical deals as follows-
No. 5- $2.72bn with 350m upfront,
No. 7- $2.5bn with 50m upfront,
No. 8- $2.15bn with 1.025bn upfront; and
No.11- $2.02bn with 120m upfront.
I believe with the latest RNS on the double ph1a trial we have been de-risked a little more and the mentioning of PK findings showing patients being able to take 1801 as a once daily treatment further underpins that de-risk.
Ofcourse a long way to go and only in ph1b Dr Readers gamechanging phase will truly show special 1801 and it's follow on 1802 are but one cannot ignore PK data it is afterall what sets and will set the roadmap for all future trials in Psoriasis and any other auto-immune indication the majors want to use it in.
Many happy returns chaps- we are aiming for end of year ph1a results, not the 12months nonsense the fud will have you believe.
Baton, 1bn dealss habe become commonplace-
The Takeda deal was actually worth $6bn as it included $2bn in sales milestones.
Also this article highlights what most think-
https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html
"We continue to expect that deals in the $5 billion to $15 billion range will be the market sweet spot"
The Takeda Nimbus deal has set the benchmark for Tyk2 in my opinion but we are Tyk2/Jak1 and our BOD believe this to be superior as we know.
All noise and distruption.
Let's concentrate on the big news here chaps Chk1 will be looked after by Cancer Research no safer hands to be honest.
The bigger picture is 1801 and 1802 both 100% owned and the fact that we are doing multi-ascending trial after just 3 cohorts.
This is what the fuds don't want to talk about as it is undeniable that insofar the science and more to the point safety mirroring pre-clinical.
Dr Mitchell mentioned that the pk finding demonstrating the capsule can be used a once daily treatment for patients- if it wasn't safe we would not be mentioning patients and you can't fud that-
"We are delighted that the data generated to date supports the safety review committee's approval to begin dosing the first subjects in the multiple ascending dose part of our Phase 1a trial of SDC-1801. Of particular importance are the pharmacokinetics findings demonstrating that patients will be able to receive SDC-1801 orally once daily.
Let the fudt.attery continue and top up before ph1b as in my opinion we are about to show parity with invivo pre-clinically in the ph1a pk data with no safety concerns, high mtd and little to no tox issues just like pre-clinical studies- a blow the bloody doors off moment.
Reality, I wouldn't worry about chk1 it's a billion figure deal in the making as ph2/3 ready showing 80% tumour reduction in combo therapy. It will happen in its own time but we only own 27.5%.
The biggy is our Tyk2's both 100% owned.
Aaah bless, were the FUD hoping no more news was in the pipeline. Well we still have the final results next month, possibly more director buys and now that 1801 has gone in both mult-ascending and concurrent ph1a trial earlier than expected and safety looks ace maybe more interest from the industry.